Photo of Bryan D. Choi, MD, PhD

Bryan D. Choi, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (330) 714-0241


bchoi@mgh.harvard.edu

Photo of Bryan D. Choi, MD, PhD

Massachusetts General Hospital
Phone: (330) 714-0241


bchoi@mgh.harvard.edu

Visualize Collaborations

Bryan D. Choi, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Neurosurgery, Harvard Medical School
  • Director, Cell Therapy for Brain Tumors, Massachusetts General Brigham Cancer Center
  • Neurosurgeon, Neurosergery, Massachusetts General Hospital

HCC PROGRAM AFFILIATION

Research Abstract

My research interests are focused on the translational development of gene-modified cell therapy and other immunotherapeutic platforms for primary brain tumors. I lead an independent laboratory and collaborate across several disciplines to develop and implement early phase clinical trials for patients with diseases of the central nervous system (CNS).

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Batool SM, Lee H, Muralidharan K, Khan SM, Escobedo AK, Gashi D, Faber K, Barretts NR, Ekanayake E, Hsia T, Al-Inaya Y, Kosgi A, Miller JJ, Cahill DP, Dunn GP, Choi BD, Petti AA, Carter BS, Balaj L. IDH1-Associated m6A Methylation Is Linked to Transcriptomic Heterogeneity in Glioma. Cancers (Basel) 2026. PubMed
  • Mazurek MH, Maguire AJ, Sixkiller JD, West TR, Perez NA, Wetzel EA, Wang AF, Gal ZT, See RB, Ritzl EK, Rapalino O, Choi BD, Nahed BV. Use of a Novel Intraoperative Neurocognitive Monitoring Task During Awake Craniotomy for Tumor Resection in the Language-Dominant Parietal Lobe. Oper Neurosurg (Hagerstown) 2026. PubMed
  • Rabbani H, Das I, Mandal AS, Nelson T, Hadar P, Hsueh B, Ciordia R, Coughlin BF, Peng E, Cleary DR, Collins KL, Raslan AMT, Williams ZM, Choi BD, Cosgrove GR, Dayeh SA, Jones PS, Tiwana HK, Dunn GP, Richardson RM, Bi WL, Tobochnik S, Cash SS, Cahill DP, Paulk AC. A modular and flexible pipeline for intraoperative electrode reconstruction and localization in patients with brain lesions. Front Neural Circuits 2026; 20:1814667. PubMed
  • Hsueh B, Steuart SJ, Odukoya AO, Prager BC, Kim YJ, Hill CM, Choi BD, Dunn GP. Immunotherapy and targeted therapy for high grade gliomas: current and future directions. J. Neurooncol. 2025; 176:112. PubMed
  • Ramapriyan R, Barker FG, Richardson LG, Sun J, Vandecandelaere G, Shim JM, De Vlaminck G, Gaffey M, Grewal EP, Tazhibi M, Morshedy K, Aref AR, Batool SM, Guo X, Ijad N, Balaj L, Wakimoto H, Martinez-Lage M, Frigault MJ, Leick MB, Bernstock JD, Bi WL, Carter BS, Chiocca EA, Dietrich J, Gerstner ER, Boland GM, Nahed BV, Plotkin SR, Jenkins RW, Brastianos PK, Curry WT, Maus MV, Choi BD. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells. 2025. PubMed
  • Park S, Maus MV, Choi BD. CAR-T cell therapy for the treatment of adult high-grade gliomas. NPJ Precis Oncol 2024; 8:279. PubMed
  • Grewal EP, Nahed BV, Carter BS, Gerstner ER, Curry WT, Maus MV, Choi BD. Clinical progress in the development of CAR T cells to treat malignant glioma. J. Neurooncol. 2024. PubMed
  • Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, Carter BS, Cahill DP, Curry WT, Choi BD. Mutant IDH modulates suppressive myeloid populations in malignant glioma. Clin Cancer Res 2024. PubMed
  • Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med 2024. PubMed
  • Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, Cahill DP, Choi BD, Curry WT. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade. Neurosurg Focus 2024; 56:E2. PubMed
  • Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 2019; 7:304. PubMed
  • Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 2019; 37:1049-1058. PubMed
Hide
Visualize Collaborations